Assembly Bill A6506A

2023-2024 Legislative Session

Prohibits the sale of xylazine

download bill text pdf

Sponsored By

Current Bill Status - In Senate Committee Consumer Protection Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

Bill Amendments

co-Sponsors

2023-A6506 - Details

See Senate Version of this Bill:
S6084
Current Committee:
Senate Consumer Protection
Law Section:
General Business Law
Laws Affected:
Add §392-k, Gen Bus L

2023-A6506 - Summary

Prohibits the sale of xylazine to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2023-A6506 - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   6506
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              April 12, 2023
                                ___________
 
 Introduced  by  M. of A. TAPIA, ZACCARO -- read once and referred to the
   Committee on Consumer Affairs and Protection
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:

   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   §  392-K.  SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION, THE TERM
 "XYLAZINE" SHALL MEAN A PHARMACEUTICAL DRUG  USED  FOR  SEDATION,  ANES-
 THESIA,  MUSCLE  RELAXATION,  AND  ANALGESIA  IN ANIMALS SUCH AS HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2. NO PERSON, CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,
 FIRM, ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITH-
 IN  THIS  STATE SHALL SELL, OFFER FOR SALE, OR DELIVER XYLAZINE TO INDI-
 VIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR INSTITUTIONAL OR SCIENTIF-
 IC PURPOSES.
   3. NO PERSON, CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,
 FIRM,  ONLINE  PLATFORM,  OR OTHER BUSINESS ENTITY DOING BUSINESS WITHIN
 THIS STATE SHALL SELL, OFFER FOR SALE, OR DELIVER XYLAZINE  TO  INDIVID-
 UALS UNDER THE AGE OF TWENTY-ONE.
   4.  ANY  PERSON,  CORPORATION, PARTNERSHIP, LIMITED LIABILITY COMPANY,
 FIRM, ONLINE PLATFORM OR OTHER BUSINESS  ENTITY  DOING  BUSINESS  WITHIN
 THIS  STATE WHICH SELLS, OFFERS FOR SALE, OR DISTRIBUTES XYLAZINE, SHALL
 REQUIRE AND RETAIN SALES RECORDS, PROOF OF AGE, AND PROOF  OF  USE  FROM
 ALL PURCHASERS.
   5.  ANY  INDIVIDUAL HARMED BY A VIOLATION OF THIS SECTION SHALL HAVE A
 PRIVATE RIGHT OF ACTION FOR COMPENSATORY AND  ACTUAL  DAMAGES,  PUNITIVE
 DAMAGES, ATTORNEYS' FEES AND COSTS.
   § 2. This act shall take effect immediately.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10463-01-3

co-Sponsors

2023-A6506A (ACTIVE) - Details

See Senate Version of this Bill:
S6084
Current Committee:
Senate Consumer Protection
Law Section:
General Business Law
Laws Affected:
Add §392-k, Gen Bus L

2023-A6506A (ACTIVE) - Summary

Prohibits the sale of xylazine to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2023-A6506A (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  6506--A
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              April 12, 2023
                                ___________
 
 Introduced  by  M.  of  A.  TAPIA,  ZACCARO,  ALVAREZ, LAVINE, RAJKUMAR,
   DE LOS SANTOS, SIMONE, REYES, SOLAGES, DICKENS, RIVERA, RAMOS, ARDILA,
   BUTTENSCHON, FORREST, SHIMSKY, LUCAS, CUNNINGHAM, CRUZ, SIMON, SAYEGH,
   EPSTEIN, BICHOTTE HERMELYN, BORES -- read once  and  referred  to  the
   Committee  on Consumer Affairs and Protection -- reported and referred
   to the Committee on  Codes  --  committee  discharged,  bill  amended,
   ordered reprinted as amended and recommitted to said committee
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   § 392-K. SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION,  THE  TERM
 "XYLAZINE"  SHALL  MEAN  A  PHARMACEUTICAL DRUG USED FOR SEDATION, ANES-
 THESIA, MUSCLE RELAXATION, AND ANALGESIA  IN  ANIMALS  SUCH  AS  HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2.  NO  PERSON,  CORPORATION,  PARTNERSHIP, LIMITED LIABILITY COMPANY,
 FIRM, ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITH-
 IN THIS STATE SHALL SELL, OFFER FOR SALE, OR DELIVER XYLAZINE  TO  INDI-
 VIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR INSTITUTIONAL, VETERINARY,
 OR SCIENTIFIC PURPOSES.
   3.  NO  PERSON,  CORPORATION,  PARTNERSHIP, LIMITED LIABILITY COMPANY,
 FIRM, ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN
 THIS  STATE  SHALL SELL, OFFER FOR SALE, OR DELIVER XYLAZINE TO INDIVID-
 UALS UNDER THE AGE OF TWENTY-ONE.
   4. ANY PERSON, CORPORATION, PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,
 FIRM,  ONLINE  PLATFORM  OR  OTHER BUSINESS ENTITY DOING BUSINESS WITHIN
 THIS STATE WHICH SELLS, OFFERS FOR SALE, OR DISTRIBUTES XYLAZINE,  SHALL
 REQUIRE  AND  RETAIN  SALES RECORDS, PROOF OF AGE, AND PROOF OF USE FROM
 ALL PURCHASERS.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10463-02-3

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.